Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biotech-drug developer Biogen Idec
So what: Though we're deep into another earnings season, Biogen's jump came from a different source: oral multiple sclerosis treatment BG-12 showed very good efficacy and fairly low risk of side effects in the second of two phase 3 FDA trials.
Now what: As an MS patient myself, I find these results very exciting: BG-12 pills seem to reduce relapses more than the baseline of Teva Pharmaceutical's
Interested in more info about Biogen Idec? Click here to add it to My Watchlist.